These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35837383)

  • 1. A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma.
    Zhang X; Min S; Yang Y; Ding D; Li Q; Liu S; Tao T; Zhang M; Li B; Zhao S; Ge R; Yang F; Li Y; He X; Ma X; Wang L; Wu T; Wang T; Wang G
    Front Immunol; 2022; 13():876355. PubMed ID: 35837383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic implications of an immune-related risk model based on TP53 status in lung adenocarcinoma.
    Song X; Chen Q; Wang J; Mao Q; Xia W; Xu L; Jiang F; Dong G
    J Cell Mol Med; 2022 Jan; 26(2):436-448. PubMed ID: 34877770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
    Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
    BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing an 8-gene immune prognostic model based on TP53 status for lung adenocarcinoma.
    Wu G; Wang Y; Wan Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24538. PubMed ID: 35689561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma.
    Liu H; Xin T; Duan H; Wang Y; Shao C; Zhu Y; Wang J; He J
    Aging (Albany NY); 2023 Jun; 15(12):5650-5661. PubMed ID: 37341998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
    Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
    BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
    Fu J; Li Y; Li C; Tong Y; Li M; Cang S
    Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
    Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
    Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
    Li H; Lu H; Cui W; Huang Y; Jin X
    Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
    Bao X; Shi R; Zhao T; Wang Y
    Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.
    Zhou B; Gao S
    Cancer Immunol Immunother; 2022 May; 71(5):1183-1197. PubMed ID: 34635925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma.
    Xu JZ; Gong C; Xie ZF; Zhao H
    Front Oncol; 2020; 10():593022. PubMed ID: 33585210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma.
    Long J; Wang A; Bai Y; Lin J; Yang X; Wang D; Yang X; Jiang Y; Zhao H
    EBioMedicine; 2019 Apr; 42():363-374. PubMed ID: 30885723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment.
    He A; Zhang R; Wang J; Huang Z; Liao W; Li Y; Wang C; Yang J; Feng Q; Wu L
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e129-e140. PubMed ID: 33852776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
    Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
    Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.